Purpose: This study was to create and validate a new therapeutic strategy which can guild clinicians to select the optimal therapy for patients with spinal cord compression resulted from metastatic cancers. Methods: The entire cohort of 206 consecutive patients was randomly divided into two groups: a training group and a validation group. For the patients randomized to the training group, we retrospectively analyzed 12 preoperative factors. The receiver operating characteristic (ROC) curve c-statistics were calculated to measure the capability of the score and the revised Tokuhashi score in the validation group. Results: Four prognostic factors, primary site (P < 0.01), preoperative ambulatory status (P ¼ 0.02), visceral metastases (P < 0.01), and preoperative chemotherapy (P ¼ 0.04), were included in the scoring model. The prognostic scores ranged between 0 and 9 points, and three prognostic groups were designed. The median survival were 3.4 months for patients with 0e2 points, 7.2 months for those with 3e5 points, and 18.3 months for those with 6e9 points, respectively (P < 0.01). In the validation group, the corresponding median survival was 3.8 months, 7.1 months, and 16.3 months, respectively (P < 0.01). The ROC curve c-statistics for the scores as a predictor of 3, 6, and 12 months survival rates were 0.74, 0.78, and 0.83 respectively, and the c-statistics for the revised Tokuhashi scores were 0.73, 0.75, and 0.75, respectively. Conclusions: We created and validated a new scoring model for predicting survival and function outcome of patients with spinal cord compression resulted from metastatic cancers after surgical decompression. This scoring model can help select the optimal therapy for those patients.
Introduction
Metastatic epidural spinal cord compression (MESCC) is an oncologic emergency and occurs in approximately 5e10% of advanced cancer patients, which, unless early diagnosed and timely treated (within 48 h), can lead to permanent neurologic deficits and seriously affect patient's quality of remaining life. 1e3 Opinions regarding the aggressiveness of the interventions to be used in this palliative context are polarized, since the most optimal treatment for MESCC are still controversial. In 2005, a prospective randomized trial strongly showed that decompressive surgery followed by radiotherapy was superior to radiotherapy alone. 4, 5 Recently, a meta-analysis also indicated that direct decompressive surgery followed by radiotherapy may produce better clinical improvement of ambulation status and survival than radiotherapy alone in 2014. 6 Generally speaking, decompressive surgery become the standard method in the treatment of MESCC, but optimal therapeutic strategies in MESCC patients still rely on accurate patient selection. Such selection should take into account patient's survival prognosis and function outcome, which can be evaluated with the prognostic scores.
Previously, we proposed scoring systems to enable physicians to identify patients with MESCC who may be the best candidates for decompressive surgery, supportive care alone, or more aggressive surgery. 7e9 However, those scoring models were especially for lung cancer or nonsmall cell lung cancer patients. We also have developed a scoring model according to the survival and functional prognosis in MESCC patients from various cancer patients, 10 while this scoring model was not validated, and one may consider five prognostic characteristic too complicated for daily routine.
Several other scoring models were developed to estimate the survival outcome of each patient and select the optimal treatment strategies. 11e17 However, the predictive accuracy of life expectancy with these traditional and commonlyused scoring models was relatively inaccurate because of the increase in survival induced by anti-cancer agents, such as molecularly targeted interventions and other adjuvant therapies, in recent years. 17e21 Moreover, function status plays an important role in advanced cancer patient's quality of remaining life, so this should be directly considered in the scoring model. Therefore, our present study was initiated to create and validate a survival scoring model and analyze function prognosis for MESCC patients from various primary cancers after decompressive surgery and spine stabilization.
Materials and methods

Patients
We retrospectively analyzed patients with MESCC who were operated with decompressive surgery between May 2005 and September 2015. The diagnosis of bone metastasis was histologically confirmed, and MESCC was proved by MRI. MESCC is radiographically defined as epidural metastatic lesion(s) leading to true displacement of the spinal cord from its normal position. Patients who were too poor to undergo surgery were not included. Patients with intradural metastasis or pathological fracture in the extremities were also excluded. Patients who had surgery for multiple MESCC (more than one site) at the same time were included. This retrospective study was proved by the Medical Research Ethics Board of the Affiliated Hospital of Academy of Military Medical Sciences.
Survival analysis
The entire cohort of patients was randomly assigned to a training group and a validation group. For patients randomized to the training group, we retrospectively analyzed twelve preoperative characteristics for postoperative survival, including age (56 years vs. >56 years; median age: 56 years), gender (female vs. male), primary site (slow growth vs. moderate growth vs. rapid growth), preoperative ambulatory status (ambulatory vs. not ambulatory), Eastern Cooperative Oncology Group (ECOG) performance status (1e2 vs. 3e4), number of involved vertebrae (1e2 vs. 3, conformed to previous studies), visceral metastases (no vs. yes), preoperative chemotherapy (no vs. yes), bone metastasis at cancer diagnosis (no vs. yes), the time developing motor deficits (14 days vs. >14 days, median time: 14 days 9 ), preoperative albumin (35 g/l vs. >35 g/l, conformed to previous studies), and radical surgery at primary site (no vs. yes).
Primary cancer was classified into three groups based on biological behavior 22 : rapid growth group (48 cases in the training group), including lung cancer without molecularly targeted drugs (30 cases), colorectal cancer (4 cases), esophageal cancer (4 cases), hepatocellular carcinoma (2 cases), head and neck cancer (1 case), melanoma (1 case), malignant thymoma (1 case), gastric cancer (0), pancreatic cancer (0), and cancers of unknown origin (5 case), moderate growth group (35 cases in the training group), including lung cancer treated with molecularly targeted drugs (18 cases), hormone-independent breast cancer (8 cases), hormone-independent prostate cancer (1 case), renal cell carcinoma (5 cases), endometrial cancer (1 case), ovarian cancer (1 case), and sarcoma (1 case), or slow growth group (20 cases in the training group), including hormone-dependent breast cancer (12 cases), hormone-dependent prostate cancer (1 case), thyroid cancer (4 cases), multiple myeloma (2 cases), and malignant lymphoma (1 case). The postoperative survival was defined as the period between the date of operation and death or the latest follow-up, and patients who were alive at the last follow-up were censored in the postoperative survival analysis. When we initially designed this study, visceral metastasis was recorded as being present or not present. In the analysis of the c-statistics for the revised Tokuhashi score, if the patients presented with visceral metastasis, they were regarded as "nonremovable".
Surgery and function analysis
The indication for surgery was neurological deficit due to MESCC. Patients were performed with posterior surgical decompression and spine stabilization. Radiotherapy, chemotherapy, or other adjuvant therapies, such as endocrine therapy and targeted therapy, were routinely performed after the wound healed, approximately 3e4 weeks after the operation. Postoperative function outcome was also analyzed according to the scoring model. Neurological function was graded according to Frankel grades before operation and 4 weeks after operation.
Statistical analysis
Patient characteristics of the training and validation groups were compared by Chi-square test. The univariate and multivariate analysis of postoperative survival in the training group were estimated by the simple and multiple Cox proportional hazards regression models, respectively. In the multivariate analysis of the training group, we included the significant characteristics for postoperative survival in the scoring model. The scoring point for each significant factor was obtained from the hazard ratios on multiple Cox proportional hazards regression model. The total prognostic score of each patient was the sum of all the scores from the significant prognostic characteristics. In the validation group, ROC curves were used to calculate the accuracy and c-statistic of the scoring model and the revised Tokuhashi scoring model for predicting 3, 6, and 12 months survival rates. The c statistic which is equivalent to the area under ROC curve is the probability of concordance between predicted and observed survival, with a value of 0.7e0.8 representing a useful scoring model and a value of more than 0.8 indicating a good scoring model. Regarding postoperative function outcome, the correlations between prognostic groups and postoperative neurological status were determined by Spearman rank correlation both in the training and the validation groups, and the ambulatory status in prognostic groups were compared with Chi-square test. Statistical significance was determined as P < 0.05, and statistical analysis was carried out using SAS 9.2 software.
Results
Patient characteristics
A cohort of two hundred and six patients was included in the study. The entire cohort of patients was randomly assigned to a training group (n ¼ 103) and a validation group (n ¼ 103). In the training group, the median overall survival was 7.9 months (95% CI, 5.6e10.9 months), 6-month survival was 57.6%, and 1-year survival rate was 35.6%. As for the validation group, the median overall survival was 7.1 months (95% CI, 6.3e9.0 months), 6-month survival rate was 61.8%, and 1-year survival rate was 30.1%. During the latest follow-up, twelve patients were alive in the training group with a median follow-up of 5.2 months (95% CI, 2.7e30.0 months). The characteristics related to both groups were summarized in Supplementary Table 1 , and it revealed that the distribution of each characteristic was similar.
Creation of a scoring model
In the univariate analysis of postoperative survival, primary site (HR, 1.96, 95% CI: 1.46e2.63; P < 0.01), preoperative ambulatory status (HR, 1.60, 95% CI: 1.04e2.47; P ¼ 0.03), visceral metastases (HR, 2.51, 95% CI: 1.62e3.90; P < 0.01), preoperative chemotherapy (HR, 2.70, 95% CI: 1.66e4.40; P < 0.01), bone metastasis at cancer diagnosis (HR, 1.66, 95% CI: 1.06e2.58; P ¼ 0.03), and radical surgery at primary site (HR, 2.28, 95% CI: 1.40e3.72; P < 0.01) were significant in the training group (Table 1 ). Of the above six potential prognostic factors, four were significantly associated with postoperative survival according to the multiple Cox proportional hazards regression model. These four significant characteristics were as follows: primary site (HR, 1.67, 95% CI: 1.22e2.27; P < 0.01), preoperative ambulatory status (HR, 1.67, 95% CI: 1.06e2.64; P ¼ 0.02), visceral metastases (HR, 2.53, 95% CI: 1.59e4.02; P < 0.01), and preoperative chemotherapy (HR, 1.73, 95% CI: 1.01e2.97; P ¼ 0.04) ( Table 1 ). The scoring points for each of the four significant characteristics obtained from the hazard ratios (rounded values) were seen in Table 2 . The total prognostic score of each patient was the sum of all the scores from the four significant prognostic characteristics. The sum resulted in prognostic scores of 0e9 points. Taking into account the 6-month survival rate and median survival time of each prognostic score, the patients of the training group were divided into three prognostic groups: 0e2 points (group A, n ¼ 30), 3e5 points (Group B, n ¼ 40), and 6e9 points (group C, n ¼ 33). The corresponding median survival were 3.4 months (95% CI, 2.7e4.5 months), 7.2 months (95% CI, 5.5e10.9 months), and 18.3 months (95% CI, 11.7e21.4 months), respectively, and the 6-month survival rates were 15.2%, 60.7%, and 90.9%, respectively (P < 0.01, Fig. S1 ).
Regarding postoperative function outcome, there was correlation between prognostic groups and postoperative neurological status in the training group (P < 0.01, Table  3 ), which indicated that the lower score the patients had, the poorer postoperative function outcome the patients suffered. In the training group, the postoperative ambulatory rates were 36.7% (11/30) in patients with 0e2 points, 85.0% (34/40) in patients with 3e5 points, and 97.0% (32/33) in patients with 6e9 points, respectively (P < 0.01). In the entire cohort of 103 patients in the training group, 74.8% (77/103) patients had the ability to walk after surgery, 60.0% (27/45) of nonambulatory patients before operation became ambulatory after surgery, and 86.2% (50/58) of ambulatory patients maintained their neurological status.
Validation of the scoring model
According to the scoring model, the corresponding median survival of the three prognostic groups in the validation group were 3.8 months (95% CI, 2.2e4.8 months) in group A (n ¼ 24), 7.1 months (95% CI, 6.3e10.2 months) in group B (n ¼ 50), and 16.3 months (95% CI, 13.6e26.0 months) in group C (n ¼ 29), and the 6-month survival rates were 13.3%, 68.1%, and 92.4%, respectively (P < 0.01, Fig. S2 ). In the validation group, the ROC curve c-statistic for the scores as a predictor of 3 months survival rate was 0.74, c-statistic as a predictor of 6 months survival rate was 0.78, and c-statistic as a predictor of 12 months survival rate was 0.83 ( Fig. 1 and Fig. S3e4 ). The accuracy rates for predicting 3, 6, and 12 months survival were 68.5%, 72.7%, and 79.1%, respectively. The predicted and observed survival rates of 3, 6, and 12 months were shown in Fig. 2 and Fig. S5e6 . The ROC curve c-statistics for the revised Tokuhashi scores as a predictor of 3 months, 6 months, and 12 months survival rate were 0.73, 0.75, and 0.75, respectively (Fig. S7e9 ). The accuracy rates for predicting 3, 6, and 12 months survival were 68.9%, 71.6%, and 71.3%, respectively.
As for function outcome, there was also correlation between prognostic groups and postoperative neurological status in the validation group (Table 3 ). In details, the ambulatory rates were 37.5% (9/24) in patients with 0e2 points, 78.0% (39/50) in patients with 3e5 points, and 93.1% (27/29) in patients with 6e9 points, respectively (P < 0.01).
Discussion
Prediction of survival for patients with metastatic spinal disease holds extremely importance, since patients selection largely depends on their survival and function prognosis. Generally speaking, patients with very poor survival and function outcome seem to be well treated with radiotherapy or even best supportive cares, while patients with a favorable survival outcome (expected survival time was greater than 3e6 months 1, 11, 13 ) and function prognosis may be potential candidates for decompressive 12 Tomita score (2001), 13 Van der Linden score (2005), 14 Sioutos score (1995), 15 Bauer score (1995), 16 and Bauer modified score. 17 However, the assessment of the available scores is mandatory to test their current availability and validity. Leithner et al. 17 evaluated the accuracy of the above seven preoperative prognostic scoring models in a series of 69 patients, and the data emphasized that only the Bauer score and Bauer modified score seemed to be practicable and predictable for patients with spinal metastasis. Tabouret et al. 18 assessed the precision of Tomita and Tokuhashi scores in patients with malignancies associated with MESCC in a cohort of 148 patients and concluded that only Tokuhashi score was relevant, but the predictive accuracy of survival was just 51%. Yu et al. 19 showed that the Tokuhashi score was not a reliable tool to predict survival in patients with spinal metastases from lung cancer, as only 8.6% patients actually followed the survivorship pattern as predicted by the Tokuhashi score. To our knowledge, those prognostic scores were proposed in the 1990s or early 2000s, but the majority of the recent anti-cancer targeted agents were available from 2005. Thanks to the development of molecularly targeted interventions and other adjuvant therapies, patients with MESCC are living longer, especially in pulmonary and renal cancers patients. 23 The underestimation of expected survival and subsequent inadequate treatment of MESCC may lead to dramatic loss of the patient's quality of remaining life. Therefore, new scoring models considering the increase in survival induced by anti-cancer agents in recent years is really needed. In 2016, Bartels et al. 24 prospectively validated the scoring model which contained five prognostic factors: sex, location of the primary lesion, intentional curative treatment of the primary tumor, cervical location of the spinal metastasis, and KPS, finding that the prediction model's overall performance was good in the records of 110 patients. The authors declared that this model can help doctors to identify surgical candidates. However, a matched pair analysis didn't find any significant difference in survival between the cervical spine metastasis and the thoracic or lumbar spine metastasis. 21 Thus, whether the location of the spinal metastasis was significantly associated with survival need further investigations.
In the present study, the scoring model was proposed according to the data derived from 206 patients with MESCC who were treated with surgical decompression and spine stabilization. Primary cancers were classified into three groups, namely, tumors that exhibited rapid growth, such as lung cancer without molecularly targeted drugs, moderate growth, such as lung cancer treated with molecularly targeted drugs and hormone-independent breast and prostate cancer, and slow growth, such as hormone-dependent breast and prostate cancer. The patient's individual situation relating to the recent anti-cancer agents is considered in the present score. Moreover, a validation group was used to confirm the scoring model. The prognostic groups of the training group were compared to the corresponding groups of the validation group: the 6-month survival rates and median survival time of the three prognostic groups in the validation group were proved to be similar to the corresponding 6-month survival rates and median survival time of the three prognostic groups in the training group, which indicated that the scoring model appeared valid and reproducible. Regarding function outcome after surgery, according to the validated scoring model, we found that there was correlation between prognostic groups and postoperative neurological status both in the training and validation groups, which suggested that the lower score the patients had, the poorer postoperative function outcome the patients suffered from. Besides, in the training group, the postoperative ambulatory rates were 36.7% in patients with 0e2 points, 85.0% in patients with 3e5 points, and 97.0% in patients with 6e9 points, respectively. As for validation group, the corresponding ambulatory rates were 37.5%, 78.0%, and 93.1%, respectively. Thus, this scoring model can also be treated as valid in terms of postoperative function outcome.
In the validation group, the ROC curve c-statistic for the scores as a predictor of 3 months survival rate was 0.74, c-statistic as a predictor of 6 months survival rate was 0.78, and c-statistic as a predictor of 12 months survival rate was 0.83, which suggested that this scoring model was a useful tool to predict survival prognosis. The ROC curve c-statistics for the revised Tokuhashi scores as a predictor of 3 months, 6 months, and 12 months survival rate were 0.73, 0.75, and 0.75, respectively. The c-statistics for the revised Tokuhashi scores were relatively lower than those for our scores, which indicated that our scoring system was relatively better than the revised Tokuhashi scoring system in predicting patient's survival prognosis. However, the therapeutic decision of patients with MESCC should never base on a prognostic score alone. To our knowledge, there is always patient's hope for a treatment that might preserve patient's ambulatory function and improve their quality of remaining life, although poor prognosis predicted by some commonly-used prognostic scores. Thus, patient's individual intention should be respected. Moreover, a hidden selection bias cannot be excluded because the present scoring model was derived from retrospective data. Therefore, the scoring model still needs a prospective study to be re-evaluated, despite positive predictive value. In conclusion, because the survival rates, survival prognosis, and postoperative function outcome of the validation group were found to be similar to those of the training group, this scoring model can be treated predictable and valid. This scoring model can help select the personalized therapy for patients with MESCC. Patients with scores of 0e2 points, who have the poorest survival prognosis (life expectancy is about 3 months) and function outcome, seem well treated with radiotherapy or supportive care. Patients with scores of 3e5 points may potentially benefit from decompressive operation due to preferable survival prognosis and function outcome after surgery, while patients with scores of 6e9 points, who have the most favorable survival prognosis and function outcome, can be treated with more aggressive surgery, which can lead to better control of local disease. This scoring model was a useful model to predict survival and function prognosis and relatively better than the revised Tokuhashi scoring model. Still, the scoring model should be re-evaluated in a prospective trial. A multicenter prospective cohort study which is registered at Chinese Clinical Trial Registry (ChiCTR-POC-16008393) is underway.
